Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Will Revise Review Order For Generic Drugs Under GIVE Project

This article was originally published in The Pink Sheet Daily

Executive Summary

First generic products – those with no blocking patents or exclusivity protections on the reference listed drug – will get expedited review, agency says.

You may also be interested in...



Gene Logic To Share Genomic Data With FDA For Critical Path Initiative

Voluntary collaboration will help FDA develop quality standards for submission of microarray data.

Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales

Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.

Affymax's Share Price Stumbles On Questionable Phase III Hematide Data

Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel